Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Chang, Yingjun  [Clear All Filters]
2024
Cao Y, Huo W, Huang J, Yang Y, Wang Y, Chang Y, Wang L, Zhang Z, Jiang C, Hu X, et al. MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study. Blood Cancer J. 2024;14(1):8.
Xiao M, Zhou J, Zhu X, He Y, Wang F, Zhang Y, Mo X, Han W, Wang J, Wang Y, et al. A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024.
Pan X'an, Chang Y, Ruan G, Zhou S, Jiang H, Jiang Q, Huang X, Zhao X-S. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database. Clin Exp Med. 2024;24(1):35.
2023
Zhao X, Wu H, Cheng Y, Xu Z, Chen Y, Chang Y, Wang Y, Zhang X, Xu L, Huang X. Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia. Chin Med J (Engl). 2023.
Lin M, Zhao X, Chang Y, Zhao X. Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy. Chin Med J (Engl). 2023.
Zhou C, Zheng F, Xu L, Zhang X, Chang Y, Mo X, Sun Y, Huang X, Wang Y. The FLT3-ITD allelic ratio and NPM1 mutation do not impact outcomes in AML patients with FLT3-ITD after allo-HSCT: a retrospective propensity-score matching study. Transplant Cell Ther. 2023.
Wei X, Chang Y, Zhu X, Hu X, Guo R, Zhang Y, Ma X, Han Y, Wang Y, Qiu H, et al. The impact of pre-transplant anti-HLA antibodies in transplants from HLA-identical sibling donors: A multicenter study. HLA. 2023.
Zhao Y, Guo H, Chang Y. MRD-directed and risk-adapted individualized stratified treatment of AML. Chin J Cancer Res. 2023;35(5):451-469.
Pan X'an, Chang Y, Ruan G, Wei F, Jiang H, Jiang Q, Huang X, Zhao X. Prognostic impact of FLT3-ITD mutation on NPM1 acute myeloid leukaemia patients and related molecular mechanisms. Br J Haematol. 2023.
2022
Wang Y, Mo X, Cheng Y, Chen Y, Lv M, Wang F, Yan C, Han W, Chen H, Xu L, et al. Effects of CD34 cell dose on haematopoietic recovery in acute lymphoblastic leukaemia patients with positive pretransplant measurable residual disease. Int J Lab Hematol. 2022.
Liu J, Wu D, Liu Q, Chang Y, Xu Y, Huang F, Huang X, Wang Y. More than two courses of consolidation therapy pre-transplantation benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study. Chin Med J (Engl). 2022.
Cai X, Fu H, Zhao X, Lu J, Jiang Q, Chang Y, Huang X, Zhang X. Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study. Chin Med J (Engl). 2022;135(19):2344-2350.
2020
Wang Y, Zhang J, Su Y, Wang C, Zhang G, Liu X, Chen Q, Lv M, Chang Y, Peng J, et al. miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. Mol Ther Nucleic Acids. 2020;20:764-776.
2019
Yu X, Cao X, Yan H, Luo X-Y, Zhao X, Sun Y, Wang Y, Xu L, Zhang X, Chang Y, et al. Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation. Clin Immunol. 2019.
Li M, Zhao W, Wang Y, Jin L, Jin G, Sun X, Wang W, Wang K, Xu X, Hao J, et al. A wave of Foxp3 regulatory T cell accumulation in the neonatal liver plays unique roles in maintaining self-tolerance. Cell Mol Immunol. 2019.